First-Line Chemo Plus Immunotherapy Falls Short in Bladder Cancer

(MedPage Today) -- Adding an immune checkpoint inhibitor to first-line platinum-based chemotherapy was not associated with clear survival benefits in advanced urothelial carcinoma, according to findings from the KEYNOTE-361 trial.
The three-arm...